Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Selection of Antibody Fragments by Yeast Display.

Scholler N.

Methods Mol Biol. 2018;1827:211-233. doi: 10.1007/978-1-4939-8648-4_12.

PMID:
30196500
2.

Molecular Imaging of Mesothelin-Expressing Ovarian Cancer with a Human and Mouse Cross-Reactive Nanobody.

Prantner AM, Yin C, Kamat K, Sharma K, Lowenthal AC, Madrid PB, Scholler N.

Mol Pharm. 2018 Apr 2;15(4):1403-1411. doi: 10.1021/acs.molpharmaceut.7b00789. Epub 2018 Feb 28.

PMID:
29462558
3.

Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.

Yuan X, Yang M, Chen X, Zhang X, Sukhadia S, Musolino N, Bao H, Chen T, Xu C, Wang Q, Santoro S, Ricklin D, Hu J, Lin R, Yang W, Li Z, Qin W, Zhao A, Scholler N, Coukos G.

Cancer Immunol Immunother. 2018 Feb;67(2):329-339. doi: 10.1007/s00262-017-2101-0.

PMID:
29313073
4.

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.

Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN.

Nat Commun. 2017 Sep 19;8(1):607. doi: 10.1038/s41467-017-00452-4.

5.

Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

Smith JB, Lanitis E, Dangaj D, Buza E, Poussin M, Stashwick C, Scholler N, Powell DJ Jr.

Mol Ther. 2016 Nov;24(11):1987-1999. doi: 10.1038/mt.2016.149. Epub 2016 Jul 21.

6.

Anti-Mesothelin Nanobodies for Both Conventional and Nanoparticle-Based Biomedical Applications.

Prantner AM, Turini M, Kerfelec B, Joshi S, Baty D, Chames P, Scholler N.

J Biomed Nanotechnol. 2015 Jul;11(7):1201-12.

PMID:
26307843
7.

Isolation and Validation of Anti-B7-H4 scFvs from an Ovarian Cancer scFv Yeast-Display Library.

Dangaj D, Scholler N.

Methods Mol Biol. 2015;1319:37-49. doi: 10.1007/978-1-4939-2748-7_2.

PMID:
26060068
8.

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD Jr, Scholler J, Scholler N, Bonneau R, June CH.

Blood. 2014 Aug 14;124(7):1070-80. doi: 10.1182/blood-2013-10-535245. Epub 2014 Jul 1.

9.

Biological barriers and current strategies for modifying nanoparticle bioavailability.

Prantner AM, Scholler N.

J Nanosci Nanotechnol. 2014 Jan;14(1):115-25. Review.

PMID:
24730254
10.

A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma.

Yuan J, Kashiwagi S, Reeves P, Nezivar J, Yang Y, Arrifin NH, Nguyen M, Jean-Mary G, Tong X, Uppal P, Korochkina S, Forbes B, Chen T, Righi E, Bronson R, Chen H, Orsulic S, Brauns T, Leblanc P, Scholler N, Dranoff G, Gelfand J, Poznansky MC.

J Hematol Oncol. 2014 Feb 24;7:15. doi: 10.1186/1756-8722-7-15.

11.

Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses.

Dangaj D, Scholler N.

Oncoimmunology. 2013 Aug 1;2(8):e25913. Epub 2013 Jul 31.

12.

Facile immunotargeting of nanoparticles against tumor antigens using site-specific biotinylated antibody fragments.

Prantner AM, Nguyen CV, Scholler N.

J Biomed Nanotechnol. 2013 Oct;9(10):1686-97.

PMID:
24015498
13.

Immunocompetent mouse model of ovarian cancer for in vivo imaging.

Nunez-Cruz S, Scholler N.

Methods Mol Biol. 2013;1049:425-33. doi: 10.1007/978-1-62703-547-7_32.

PMID:
23913235
14.

Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.

Dangaj D, Lanitis E, Zhao A, Joshi S, Cheng Y, Sandaltzopoulos R, Ra HJ, Danet-Desnoyers G, Powell DJ Jr, Scholler N.

Cancer Res. 2013 Aug 1;73(15):4820-9. doi: 10.1158/0008-5472.CAN-12-3457. Epub 2013 May 30.

15.

Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.

Nunez-Cruz S, Gimotty PA, Guerra MW, Connolly DC, Wu YQ, DeAngelis RA, Lambris JD, Coukos G, Scholler N.

Neoplasia. 2012 Nov;14(11):994-1004.

16.

Coating Evaluation and Purification of Monodisperse, Water-Soluble, Magnetic Nanoparticles Using Sucrose Density Gradient Ultracentrifugation.

Prantner AM, Chen J, Murray CB, Scholler N.

Chem Mater. 2012 Nov 13;24(21):4008-4010. Epub 2012 Oct 19. No abstract available.

17.

Selection of antibody fragments by yeast display.

Scholler N.

Methods Mol Biol. 2012;907:259-80. doi: 10.1007/978-1-61779-974-7_15.

PMID:
22907357
18.

Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library.

Li Y, Siegel DL, Scholler N, Kaplan DE.

BMC Biotechnol. 2012 May 7;12:23. doi: 10.1186/1472-6750-12-23.

19.

A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.

Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, Yu J, Scholler N, Powell DJ Jr.

Cancer Res. 2012 Apr 1;72(7):1844-52. doi: 10.1158/0008-5472.CAN-11-3890. Epub 2012 Feb 7.

20.

Oncology biomarkers for gynecologic malignancies.

Tanyi JL, Scholler N.

Front Biosci (Elite Ed). 2012 Jan 1;4:1097-110.

PMID:
22201939
21.

Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody.

Dangaj D, Abbott KL, Mookerjee A, Zhao A, Kirby PS, Sandaltzopoulos R, Powell DJ Jr, Lamazière A, Siegel DL, Wolf C, Scholler N.

PLoS One. 2011;6(12):e28386. doi: 10.1371/journal.pone.0028386. Epub 2011 Dec 6.

22.

Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.

Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ Jr.

Mol Ther. 2012 Mar;20(3):633-43. doi: 10.1038/mt.2011.256. Epub 2011 Nov 29.

23.

Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.

Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, Jiang SW, Podratz K, Urban N, Dowdy SC.

Gynecol Oncol. 2012 Feb;124(2):270-5. doi: 10.1016/j.ygyno.2011.10.025. Epub 2011 Oct 28.

24.

Potential role of HE4 in multimodal screening for epithelial ovarian cancer.

Urban N, Thorpe JD, Bergan LA, Forrest RM, Kampani AV, Scholler N, O'Briant KC, Anderson GL, Cramer DW, Berg CD, McIntosh MW, Hartge P, Drescher CW.

J Natl Cancer Inst. 2011 Nov 2;103(21):1630-4. doi: 10.1093/jnci/djr359. Epub 2011 Sep 14.

25.

Novel surface targets and serum biomarkers from the ovarian cancer vasculature.

Sasaroli D, Gimotty PA, Pathak HB, Hammond R, Kougioumtzidou E, Katsaros D, Buckanovich R, Devarajan K, Sandaltzopoulos R, Godwin AK, Scholler N, Coukos G.

Cancer Biol Ther. 2011 Aug 1;12(3):169-80. Epub 2011 Aug 1.

26.

A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.

Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD; PLCO Project Team.

Cancer Prev Res (Phila). 2011 Mar;4(3):375-83. doi: 10.1158/1940-6207.CAPR-10-0193.

27.

Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N.

Cancer Prev Res (Phila). 2011 Mar;4(3):365-74. doi: 10.1158/1940-6207.CAPR-10-0195.

28.

An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses.

Nunez-Cruz S, Connolly DC, Scholler N.

J Vis Exp. 2010 Nov 28;(45). pii: 2146. doi: 10.3791/2146.

29.

Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform.

Zhao A, Nunez-Cruz S, Li C, Coukos G, Siegel DL, Scholler N.

J Immunol Methods. 2011 Jan 5;363(2):221-32. doi: 10.1016/j.jim.2010.09.001. Epub 2010 Sep 15.

30.

Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.

Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N, O'Briant K, Drescher C, Urban N.

J Natl Cancer Inst. 2010 Jan 6;102(1):26-38. doi: 10.1093/jnci/djp438. Epub 2009 Dec 30.

31.

Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.

Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P, Urban N.

Gynecol Oncol. 2010 Mar;116(3):378-83. doi: 10.1016/j.ygyno.2009.10.087. Epub 2009 Nov 28.

32.

Antifouling surface layers for improved signal-to-noise of particle-based immunoassays.

Chen A, Kozak D, Battersby BJ, Forrest RM, Scholler N, Urban N, Trau M.

Langmuir. 2009 Dec 1;25(23):13510-5. doi: 10.1021/la903148n.

33.

Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?

Sasaroli D, Coukos G, Scholler N.

Biomark Med. 2009 Jun 1;3(3):275-288.

34.

Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.

Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD, Urban N, Drescher CW.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1365-72. doi: 10.1158/1055-9965.EPI-08-1034.

36.

Maternal mortality from systemic illness: unraveling the contribution of the immune response.

Gonzalez JM, Ofori E, Burd I, Chai J, Scholler N, Elovitz MA.

Am J Obstet Gynecol. 2009 Apr;200(4):430.e1-8. doi: 10.1016/j.ajog.2009.01.049.

PMID:
19318152
37.

Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.

Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, Andersen MR, Scholler N, Bergan L, Thorpe J, Urban N, Drescher CW.

Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2480-7. doi: 10.1158/1055-9965.EPI-08-0150.

38.

Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery.

Scholler N, Gross JA, Garvik B, Wells L, Liu Y, Loch CM, Ramirez AB, McIntosh MW, Lampe PD, Urban N.

J Transl Med. 2008 Jul 24;6:41. doi: 10.1186/1479-5876-6-41.

39.

Combining a symptoms index with CA 125 to improve detection of ovarian cancer.

Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Dresher CW, Paley P, Urban N.

Cancer. 2008 Aug 1;113(3):484-9. doi: 10.1002/cncr.23577.

40.

Systematic evaluation of candidate blood markers for detecting ovarian cancer.

Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW, Brown PO, Nelson BH, Urban N.

PLoS One. 2008 Jul 9;3(7):e2633. doi: 10.1371/journal.pone.0002633.

41.

A mouse to human search for plasma proteome changes associated with pancreatic tumor development.

Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, Hanash SM.

PLoS Med. 2008 Jun 10;5(6):e123. doi: 10.1371/journal.pmed.0050123.

42.

Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.

Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R, Anderson GL, Urban N.

Clin Cancer Res. 2008 May 1;14(9):2647-55. doi: 10.1158/1078-0432.CCR-07-1442.

43.

CA125 in ovarian cancer.

Scholler N, Urban N.

Biomark Med. 2007 Dec;1(4):513-23. doi: 10.2217/17520363.1.4.513.

44.

Use of high density antibody arrays to validate and discover cancer serum biomarkers.

Loch CM, Ramirez AB, Liu Y, Sather CL, Delrow JJ, Scholler N, Garvik BM, Urban ND, McIntosh MW, Lampe PD.

Mol Oncol. 2007 Dec;1(3):313-20. doi: 10.1016/j.molonc.2007.08.004. Epub 2007 Aug 30.

45.

Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment.

Bergan L, Gross JA, Nevin B, Urban N, Scholler N.

Cancer Lett. 2007 Oct 8;255(2):263-74. Epub 2007 Jun 7.

PMID:
17560019
46.

Method for generation of in vivo biotinylated recombinant antibodies by yeast mating.

Scholler N, Garvik B, Quarles T, Jiang S, Urban N.

J Immunol Methods. 2006 Dec 20;317(1-2):132-43. Epub 2006 Oct 30.

47.

Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.

Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, Urban N.

Cancer Lett. 2007 Mar 8;247(1):130-6. Epub 2006 May 4.

48.

Bead-based ELISA for validation of ovarian cancer early detection markers.

Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, Kiviat N, Anderson GL, Urban N.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2117-24.

49.

Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I.

Gynecol Oncol. 2004 Oct;95(1):9-15.

50.

Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity.

Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellström KE, Hellström I.

Mol Cancer Ther. 2003 Oct;2(10):995-1002.

Supplemental Content

Loading ...
Support Center